Company News
- Cyclo Therapeutics Unveils New Corporate Identity and Reaffirms Commitment to Improving Quality of Life and Providing Hope for Patients and Families
Feb 22, 2021, 9:00 AM EST - Cyclo Therapeutics Presents Positive Data from Clinical Development Program for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2021
Feb 9, 2021, 8:05 AM EST - Cyclo Therapeutics to Present on Its Clinical and Drug Development Program for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2021
Jan 26, 2021, 8:00 AM EST - Cyclo Therapeutics Announces Positive Efficacy Data from Extension Protocol with Trappsol® Cyclo™ in Patients with Niemann-Pick Disease Type C
Jan 5, 2021, 8:00 AM EST - Cyclo Therapeutics Announces Closing of Underwriters’ Option to Purchase Additional Shares of Common Stock in Connection with its Underwritten Public Offering
Dec 22, 2020, 2:30 PM EST - Cyclo Therapeutics Announces Pricing of $12.5 Million Public Offering
Dec 9, 2020, 12:52 PM EST - Cyclo Therapeutics Announces Two Presentations at WORLDSymposium2021
Nov 19, 2020, 8:00 AM EST - Cyclo Therapeutics Phase 3 Pivotal Program Can Begin Enrollment Per US FDA
Oct 21, 2020, 10:53 AM EDT - Cyclo Therapeutics to Present at 2020 Annual Conference for NPC Patients, Families, and Health Professionals in the United Kingdom
Sep 21, 2020, 8:00 AM EDT - Cyclo Therapeutics Inc. Announces Additional Efficacy Data from its Ongoing Phase I/II Trial using Trappsol® CycloTM Intravenously to Treat Patients with Niemann-Pick Disease Type C1 (NPC1)
Sep 8, 2020, 8:38 AM EDT
